Drug Trial Radar · NCT04426890
To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
634
Actual
Start
Dec 9, 2020
Primary completion
Oct 21, 2022
Study completion Apr 27, 2023
Sponsor
- Lead sponsor
- CelltrionIndustry
- Sponsor type
- Industry
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine Treatment
Conditions
- Chronic Spontaneous Urticaria
Interventions
CT-P39Biological
Prefilled syringe (PFS) of 1 mL solution
EU-approved XolairBiological
Prefilled syringe (PFS) of 1 mL solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg GroupsTime frame: Week 12
- Relative Potency of CT-P39 Compared With Xolair Based on Change From Baseline in ISS7 at Week 12Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinika Ambroziak ESTEDERM
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.